肝硬化肝脏海绵状血管瘤的硬化性改变:动态增强CT长期随访
研究对41例肝硬化患者的57个肝血管瘤(>5 mm)进行长期CT随访(中位7.8年),发现63%出现硬化性改变、49%直径缩小≥20%;背景肝硬化形态学进展是独立预测因素(OR 4.88,P=0.007),外生性病灶则倾向于不缩小。
要点
- 肝硬化患者肝血管瘤随访中约63%出现硬化性改变,49%直径缩小≥20%。
- 背景肝硬化形态学进展是血管瘤硬化性改变的独立预测因素(OR 4.88,P=0.007)。
- 外生性病灶在多变量分析中与无尺寸缩小相关(P=0.023),与硬化性改变无显著相关。
关键影像表现/征象
- 57个血管瘤中36个(63%)在随访期(1.1–14.4年,中位7.8年)出现硬化性CT表现。
- 其中28个病灶(49%)直径缩小≥20%。
- 外生性病灶在多变量分析中与无尺寸缩小相关(P=0.023),但与硬化性改变无其他因素显著相关。
诊断标准与关键数值
- 硬化性改变依据动态CT特征判定,57个血管瘤中36个(63%)出现。
- 直径缩小≥20%者28个(49%)。
- 单变量分析:年龄(P=0.047)与背景肝硬化形态学进展(P=0.013)与血管瘤硬化性改变显著相关。
- Logistic回归:仅背景肝硬化形态学进展独立预测硬化性改变(OR 4.88,P=0.007)。
- 多变量分析:外生性位置与无尺寸缩小相关(P=0.023);除此之外无其他分析因素与硬化性改变显著相关。
临床应用与阅片要点
- 随访肝硬化患者肝血管瘤时,背景肝硬化的形态学进展提示病灶可能出现硬化性改变。
- 外生性血管瘤在随访中可能不出现尺寸缩小,判读时需结合位置考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine the intra- and extralesional factors that predict sclerotic degeneration of hepatic hemangiomas in the cirrhotic liver on long-term follow-up computed tomography (CT) examinations.
MATERIALS AND METHODS: Fifty-seven hepatic hemangiomas (> 5 mm in diameter) in 41 cirrhotic patients, recruited over a 5-year period (January 2005-December 2009), were subjected to CT to determine which factors predict sclerotic contraction or degeneration in hemangiomas. Prior and follow-up CT examinations (from 2000 to 2018) were included to observe time-related changes. The patients' gender, age, cause of cirrhosis, progression of background liver cirrhosis, lesion size/location/contrast enhancement pattern, and serum aspartate transaminase to platelet ratio index were correlated with sclerotic changes of each lesion.
RESULTS: According to the dynamic CT features, 36 of 57 (63%) hemangiomas were determined to have sclerotic changes during the follow-up period (1.1-14.4 years, median: 7.8 years), including 28 lesions (49%) reduced by ≥ 20% in diameter. In univariate analysis, age (p = 0.047) and morphological progression of background cirrhosis (p = 0.013) were significantly related to sclerotic change of hemangiomas. In the logistic regression analysis, only morphological progression of background liver cirrhosis independently predicted sclerotic change (odds ratio: 4.88, p = 0.007). With the exception of exophytic location free from size reduction (p = 0.023 in multivariate analysis), no other analyzed factors were significantly correlated with sclerotic changes.
CONCLUSION: Overall, sclerotic changes of hepatic cavernous hemangioma followed the morphological progression of background liver cirrhosis, while exophytic lesions tended to be free of size reduction.
引用
- Shin N, Choi JA, Choi JM, et al. Sclerotic changes of cavernous hemangioma in the cirrhotic liver: long-term follow-up using dynamic contrast-enhanced computed tomography. Radiol Med. 2020. PMID: 32415477. doi:10.1007/s11547-020-01221-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。